透析患者中mRNA-based BNT162b2疫苗与腺病毒载体Ad26.COV2.S疫苗预防COVID-19的比较有效性
这项回顾性研究在2572对匹配的透析患者中比较了BNT162b2与Ad26.COV2.S疫苗的临床有效性,发现接种后前6个月内两组COVID-19累积发病率、住院和死亡均无差异,但Ad26.COV2.S接种者中仅59.4%检出SARS-CoV-2抗体。
要点
- 在2572对匹配透析患者中,BNT162b2与Ad26.COV2.S接种后COVID-19累积发病率无差异。
- 两组COVID-19相关住院和死亡无差异,亚组及排除既往感染者后结果相似。
- Ad26.COV2.S接种者中59.4%(244例中)检出SARS-CoV-2抗体。
核心结论
- 在大型真实世界透析患者队列中,接种后前6个月内BNT162b2与Ad26.COV2.S的临床有效性未检测到差异,尽管后者抗体应答不一致。
研究设计与样本
- 回顾性研究,比较腺病毒载体Ad26.COV2.S与mRNA-based BNT162b2在透析患者中的临床有效性。
- 基于首次接种日期、美国居住州、透析地点(中心 vs 家庭)、COVID-19病史和倾向评分,将接受首剂BNT162b2的患者与Ad26.COV2.S接种者按1:1匹配。
- 主要结局为接种后第7周起的COVID-19诊断比较率。
- 在部分知情同意的Ad26.COV2.S接种者中,于接种后≥28天采集血样检测抗SARS-CoV-2免疫球蛋白G抗体。
主要发现
- 共2572对匹配患者纳入分析。
- BNT162b2与Ad26.COV2.S的COVID-19累积发病率无差异。
- 在风险期内诊断为COVID-19的患者中,接受BNT162b2与Ad26.COV2.S者的围COVID-19住院和死亡无差异。
- 排除有COVID-19病史者、限制于完成两剂BNT162b2方案者的亚组分析以及接受中心血液透析的患者中,结果相似。
- 244例接受Ad26.COV2.S的患者中,59.4%检出SARS-CoV-2抗体。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies have demonstrated that mRNA-based SARS-CoV-2 vaccines are highly effective among patients on dialysis. Because individual vaccines may be differentially available or acceptable to patients, it is important to understand comparative effectiveness relative to other vaccines, such those on the basis of adenovirus technologies. METHODS: In this retrospective study, we compared the clinical effectiveness of adenovirus vector-based Ad26.COV2.S (Janssen/Johnson & Johnson) to mRNA-based BNT162b2 (Pfizer/BioNTech) in a contemporary cohort of patients on dialysis. Patients who received a first BNT162b2 dose were matched 1:1 to Ad26.COV2.S recipients on the basis of date of first vaccine receipt, US state of residence, site of dialysis care (in-center versus home), history of COVID-19, and propensity score. The primary outcome was the comparative rate of COVID-19 diagnoses starting in the 7th week postvaccination. In a subset of consented patients who received Ad26.COV2.S, blood samples were collected ≥28 days after vaccination and anti-SARS-CoV-2 immunoglobulin G antibodies were measured. RESULTS: A total of 2572 matched pairs of patients qualified for analysis. Cumulative incidence rates of COVID-19 did not differ for BNT162b2 versus Ad26.COV2.S. No differences were observed in peri-COVID-19 hospitalizations and deaths among patients receiving BNT162b2 versus Ad26.COV2.S, who were diagnosed with COVID-19 during the at-risk period. Results were similar when excluding patients with a history of COVID-19, in subgroup analyses restricted to patients who completed the two-dose BNT162b2 regimen, and in patients receiving in-center hemodialysis. SARS-CoV-2 antibodies were detected in 59.4% of 244 patients who received Ad26.COV2.S. CONCLUSIONS: In a large real-world cohort of patients on dialysis, no difference was detected in clinical effectiveness of BNT162b2 and Ad26.COV2.S over the first 6 months postvaccination, despite an inconsistent antibody response to the latter.
引用
- Brunelli SM, Sibbel S, Karpinski S, et al. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients. J Am Soc Nephrol. 2022. PMID: 35135894. doi:10.1681/ASN.2021101395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。